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ABSTRACT
Background Asthma is a common, heterogeneous 
disease that is characterised by chronic airway 
inflammation and variable expiratory airflow limitation. 
Current guidelines use spirometric measures for asthma 
assessment. This systematic review aimed to assess 
whether the most commonly reported tests of small 
airways function could contribute to the diagnosis of 
asthma.
Methods Standard systematic review methodology was 
used, and a range of electronic databases was searched 
(Embase, MEDLINE, CINAHL, CENTRAL, Web of Science, 
DARE). Studies that included physiological tests of small 
airways function to diagnose asthma in adults were 
included, with no restrictions on language or date. The risk 
of bias and quality assessment tools used were Agency for 
Healthcare Research and Quality tool for cross- sectional 
studies and Quality Assessment of Diagnostic Accuracy 
Studies 2 for diagnostic test accuracy (DTA) studies.
Results 7072 studies were identified and 10 studies met 
review criteria. 7 included oscillation techniques and 5 
included maximal mid- expiratory flow (MMEF). Studies 
were small and of variable quality. In oscillometry, total 
resistance (R5) and reactance at 5 Hz (X5) was altered in 
asthma compared with healthy controls. The percentage 
predicted of MMEF was lower in patients with asthma 
compared with controls in all studies and lower than the 
% predicted forced expiratory volume in 1 s. In DTA of 
oscillometry, R5 showed a sensitivity between 69% and 
72% and specificity between 61% and 86%.
Conclusion There were differences in the results of 
physiological tests of small airway function in patients 
with asthma compared with controls. However, studies are 
small and heterogeneous. Further studies are needed to 
assess the effectiveness of these tests on a larger scale, 
including studies to determine which test methodology is 
the most useful in asthma.
BACKGROUND
Asthma is a common but heterogeneous 
disease characterised by chronic airway inflam-
mation and clinically defined by the presence 
of respiratory symptoms that vary over time 
and in intensity. Physiologically, asthma is 
characterised by variable expiratory airflow 
limitation which may become persistent over 
time.1 Symptoms and airflow limitation can 
be extremely variable, including the age of 
onset, triggers for symptoms, the decline in 
lung function and therapeutic response.
It is estimated that 339 million people are 
affected by asthma globally1 but diagnosing 
asthma is often challenging as there is no gold 
standard test. This has led to a high burden 
of undiagnosed disease, especially in children 
and older adults.2 3 According to current 
guidelines,1 4 a diagnosis of asthma should be 
objectively supported with an assessment of 
forced expiratory volume in 1 s (FEV1) revers-
ibility. However, some patients with asthma 
have no evidence of reversibility or airflow 
obstruction5 6 and airflow obstruction and 
reversibility are seen in patients with alter-
native diagnoses such as chronic obstructive 
pulmonary disease (COPD).7 8 Furthermore, 
the forced manoeuvres required for spirom-
etry requires effort and coordination, which 
can be difficult for some individuals.9
In the past, asthma was thought to only 
affect larger airways10 but current evidence 
suggests that small airways (defined as 
airways of ≤2 mm in diameter) are affected 
as well. The small airways may form a site of 
active disease, even in the absence of airflow 
Key messages
 ► Is there evidence to support the use of physiological 
tests of small airways function in the diagnosis of 
asthma?
 ► There is evidence of small airways dysfunction in 
asthma, which some physiological tests can identify. 
However, studies are small and heterogeneous and 
more studies are needed to understand the clinical 
utility of these tests.
 ► This systematic review provides a summary of the 
current evidence around physiological tests of small 
airways and asthma. It includes recommendations 
for the future work required to before the adoption 
of physiological small airways tests in the diagnosis 
of asthma.
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obstruction.11 If the small airways are the first to be 
affected in asthma, identifying small airways dysfunction 
(SAD) may help identify asthma earlier, enabling treat-
ment. However, there are a large number of tests that 
report small airways function. Some of these are being 
used as secondary outcomes in experimental studies of 
asthma, to determine asthma phenotype and assess the 
response to new therapies.12 The evidence to support the 
use of any physiological test of small airways function in 
the diagnosis of asthma is unclear.
This systematic review aimed to assess the evidence to 
support the use of commonly reported physiological tests 
of small airways function to diagnose asthma in adults, 
and assess if the selected tests should be included in 
future clinical studies of the disease.
METHODS
The protocol was prospectively registered in the interna-
tional registry of systematic reviews (PROSPERO) with 
registration number CRD42019133239. The review was 
prepared in accordance to the Preferred Reporting Items 
for Systematic Reviews and Meta- Analyses (PRISMA) 
guidelines13 and the PRISMA checklist is provided in 
online supplemental material file S1. Meta- analysis was 
considered where homogenous results were provided, 
otherwise data were pooled for graphical presentational 
purposes.
Through both scoping searches and discussion with 
experts, the following test were selected to be included in 
the search, forced oscillation technique (FOT), impulse 
oscillometry (IOS) and maximal mid- expiratory flow 
(MMEF) also known as forced expiratory flow between 
25% and 75% of forced vital capacity (FVC) (FEF25%–
75%), and multiple breath washout test (MBW). These 
tests were selected as they represented some of the most 
commonly reported physiological tests of small airways 
function in obstructive lung disease in adults. Online 
supplemental figure S2 shows the Population, Interven-
tion, Comparison and Outcome (PICO) chart with the 
studies selection criteria.
Eligibility criteria
Studies were considered for inclusion if they used one 
of the proposed physiological small airways function tests 
(FOT/IOS, MBW, MMEF) in diagnosing asthma in adults 
aged >18 years old. Patients with either a physician diag-
nosis or a suspected diagnosis of asthma were considered 
for inclusion. FEV1 was used as the comparator as it is 
the current standard in physiological airway assessment. 
Studies were excluded if they included only children 
(<18 years), patients with respiratory infections within 2 
months of the assessment, did not assess FEV1, included 
patients with asthma- COPD overlap, were laboratory- 
based studies, animal- based studies or case series of less 
than 10 participants. There were no language or publica-
tion date restrictions.
Search queries were carried out in May 2019 (and 
the detailed search strategy is found in online supple-
mental material file S3) on the following electronic 
databases: Embase, MEDLINE, CINAHL, Cochrane 
Central Register of Controlled Trials (CENTRAL), Web 
of Science (Abstracts and Proceedings) up to 5 years and 
DARE database for grey literature.  Clinicaltrials. gov and 
EudraCT were also searched for active trials or published 
data. Hand searching of references listed in the selected 
articles was included. Search terms contained subject 
heading and terms for the selected test (IOS/FOT, MBW 
and MMEF) combined with terms of asthma and small 
airways function.
Study selection
Search results were imported into EndNote 9.1 (Clarivate 
Analytics) where duplicates were removed and data was 
uploaded to Rayyan14 (a webapp tool used for screening 
titles and abstracts). Abstracts were screened blindly and 
independently by the authors MA and NYA using the 
predefined inclusion and exclusion criteria. Disagree-
ments were resolved by discussion, otherwise by the third 
reviewer, whose initials were RGE. Full- text articles were 
acquired and imported into EndNote 9.1 by author MA 
and similar abstract screening methodology was used in 
screening full texts for eligibility.
Data extraction
Data were extracted by author MA and checked by author 
NYA for consistency and accuracy using a custom, piloted 
data extraction form. Diagnostic criteria used to iden-
tify asthma, tests used to aid the diagnosis such as airway 
reversibility, asthma severity, phenotype, medications, 
the device used and comorbidities were extracted to aid 
narrative review and provide clinical context. Studies 
were categorised based on the small airways test used. 
In diagnostic test accuracy (DTA) studies, sensitivity and 
specificity values were extracted and a 2×2 contingency 
table was calculated.
Quality and risk of bias assessment
Quality and risk of bias were assessed using validated 
tools based on study design. Cross- sectional studies were 
assessed using the Agency for Healthcare Research and 
Quality (AHRQ) checklist tool.15 The Quality Assessment 
of Diagnostic Accuracy Studies 216 (QUADAS-2) was used 
in DTA. The QUADAS-2 tool assesses the risk of bias of 
studies over four domains: flow and timing, reference 
standard, index test and patient selection. The tool also 
assesses for applicability concerns under three domains: 
reference standard, index test and patient selection.
Descriptions of the tests of small airways function included in the 
reported studies
Here, only tests included in the analysed studies are 
described.
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Oscillometry
Oscillometry can be assessed using either the FOT or 
IOS. Oscillometry transmits oscillating sound signals of 
various frequencies along the bronchial tree, providing 
a measure of the total airway resistance (resistance at 5 
Hz (R5)) and the proximal airway resistance (resistance 
at 20 Hz (R20)), which allows for the derivation of small 
airways resistance (R5–R20). Reactance at 5 Hz (X5) 
relates to physical properties of the lung parenchyma and 
its ability to expand and facilitate alveolar filling. Reso-
nant frequency (Fres) is the point at which reactance is 
zero (when forces of inertia and capacitance are equal). 
The area of reactance (AX) is the sum of area under the 
reactance curve between X5 and Fres.17 18 Limitations 
with this technique include the lack of universal normal 
ranges for all populations and variance of results between 
different devices, which can impede interpretation.19
Maximum mid-expiratory flow
The MMEF is the mean forced expiratory flow between 
25% and 75% of the FVC (FEF25%–75%) and is taken from 
the spirometric blow with the largest sum of FEV1 and 
FVC. The MMEF is highly dependent on the validity of the 
FVC measurement and the level of expiratory effort.20 21 
MMEF is commonly reported in studies of small airways 
as it is readily accessible from spirometry reports.
Patient and public involvement
Due to the nature of the study design, patients and public 
were not involved in this systematic review.
RESULTS
Study selection
Initial searches identified 7072 abstracts. After the 
removal of duplicates, 5764 abstracts were screened of 
which 469 abstracts included for full text screening. Ten 
articles ultimately met the inclusion criteria (figure 1 
shows the Preferred Reporting Items for Systematic 
Reviews and Meta- Analyses flow diagram). Articles 
excluded in the full- text screening phase are described in 
online supplemental material file S4 with reasons given. 
All included studies were cross- sectional in design and 
3/10 of the included studies were DTA studies.
Study characteristics
Seven of the included articles reported oscillometry 
(IOS/FOT)22–28 and five reported MMEF.23 29–31 None of 
the included studies reported MBW use in diagnosing 
asthma. Seven studies were not designed as DTA studies 
and are presented in table 1. Three studies were designed 
as DTA studies and these are presented in table 2. The 
diagnostic criteria used to confirm a diagnosis of asthma 
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta- Analyses flow chart of included studies.
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differed among studies. Four studies used Global Initi-
ative for Asthma guidelines,24 25 28 30 one American 
Thoracic Society guidelines27 and one the global strategy: 
Joint Report of the National Institute for Heart, Lungs 
and Blood and WHO.29 Three studies recruited patients 
based on a previous diagnosis of asthma, without reporting 
the diagnosis criteria used.22 23 26 One study reported 
that patients with symptoms of asthma were included 
without any formal diagnosis.31 All included studies were 
based in different countries (the USA, UK, Japan, Korea, 
Turkey, Egypt, Russia, Serbia, Iran and China) from 
four different continents (North America, Europe, Asia 
and Africa) making the ethnicity of participants heter-
ogeneous. Body mass index (BMI) was only reported in 
three of the included studies.23–25 Meta- analysis of the 
data were inappropriate due to the variety and scope of 
methodological design. Where appropriate, data were 
displayed graphically to aid the representation of results. 
No MMEF studies explicitly corrected for FVC, which can 
potentially affect interpretation.
Risk of bias
Two risk of bias and quality assessment tools were used 
in this systematic review, based on the design of the 
included studies. Seven studies were assessed using the 
AHRQ tool for cross- sectional studies15 (see figure 2A). 
This highlighted potential methodological issues around 
subject selection and quality assurance concerns, which 
may have impacted on the reliability of results and the 
Table 1 The characteristics of included studies without a diagnostic test accuracy analysis










66 kg (12)* NR Asthma:
MMEF% 69 (20)
R8 cmH2O 2.91 (0.99)
Control:
MMEF 93% (20)



















X5 cmH2O −0.96 (1.03)
R5–R20 cmH2O 0.86 (0.62)
R5 cmH2O 4.2 (1.43)
Control:
MMEF 88.9 (22.1)
X5 cmH2O −0.05 (0.27)
R5–R20 cmH2O 0.32 (0.44)

















X5 (Unit NR) −2.87 (1.84)
Control:
R5% 109.25 (19.40)







Asthma 31 23 (5) NR IOS- 
Masterscreen
Asthma:
X5 kPa −0.09 (0.05)
AX kPa 0.23 (0.16)
R5 kPa 0.34 (0.09)






























Asthma 125 43 (1) NR NR 1. MMEF% 97.67 (3.48)
2. MMEF% 95.08 (5.74)








Values reported in mean (SD).
*Weight in kg.
†Values reported in mean (SEM).
BMI, body mass index; FEV1, forced expiratory volume in 1 s; FOT, forced oscillation technique; GINA, Global Initiative for Asthma; ID, study 
identification (authors) country, research type; IOS, impulse oscillometry; NR, not reported; SA, small airways.
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reporting of study follow- up. There was an overall low 
risk of bias around patient recruitment (including the 
source of subjects), the inclusion/exclusion criteria and 
time periods when patients were identified. Response 
rates and completeness of results were all reported. A 
summary of all included studies using both tools is avail-
able in online supplemental material file S5.
Three studies were assessed using QUADAS-2 tool for 
DTA studies (see figure 2B). One study had a high risk 
of bias and applicability concern in the patient selection 
phase. Two studies had a high risk of bias in the index 
test.
Results of individual studies
Oscillometry
Seven studies used oscillometry. One study used FOT,24 
five studies used IOS22 25–28 and one study did not 
reported which type of oscillometry was used.23 Five 
studies reported R5,22–26 which represent the total lung 
resistance. Only one study reported R5–R20.24 The values 
of the test were reported in different units with Mori et al24 
and Mendonça et al23 reporting results in cmH2O/L/s, 
Nair et al26 and Mousa and Kamal the % predicted values 
and Koruga et al22 and Nikkhah et al28 in kPa/L/s.
Mori et al24 reported R5, R5–R20, X5 and MMEF in 49 
asthmatic patients,13 controls and 51 COPD patients. 
They described differences in MMEF, R5- R20 and X5 
when comparing asthma to control subjects but not 
R5. In addition, they reported that the coloured three- 
dimensional model provided by the FOT device could 
differentiate between asthma, COPD and healthy subjects, 
with a higher resistance and lower reactance observed in 
asthma. Asthma severity was not reported and 24 of the 
asthmatic subjects were ex- smokers.
Mendonça et al23 studied 35 asthmatic and 34 non- 
asthmatic participants but used a different technique 
and frequency than the commonly reported value. Oscil-
lometry values were reported in cmH2O/L/s. The whole 
breath resistance at 8 Hz (R8) and the minimum resis-
tance at maximum inhalation Rmin were both different 
when comparing the asthmatic (R8=2.91±0.99) and 
non- asthmatic group (R8=2.21±0.48). In the asth-
matic patients, both the MMEF % predicted value was 
lower (69%±20) than healthy controls (93%±20) and 
a higher Rmin was observed. They also conducted a 
methacholine challenge test (MCT) in all participants 
and found that (31/35) asthmatic subject and (8/34) 
non- asthmatic group had a positive result. A subgroup 
analysis was reported including asthmatics with positive 
MCT (31/35) and non- asthmatic with a negative MCT 
(26/34) and similar results were reported to the overall 
analysis with a higher Rmin in positive MCT (1.41±0.42) 
compared with (1.02±0.24) in negative MCT. Moreover, 
MMEF was lower in the MCT positive group (68%±18) 
compared with (99%±18) in negative MCT group. The 
mean FEV1 was 88%±11 predicted in the asthmatic group 
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within the normal range. The authors examined the 
ability of MMEF, Rmin and FEV1 to predict airway hyper- 
responsiveness to methacholine by producing a receiver 
operating characteristic (ROC) curve which showed that 
MMEF had the highest area under the curve (AUC) of 
0.87, while Rmin and FEV1 had AUC of 0.85 and 0.78, 
respectively. R8 was not reported in the ROC curve.
Mousa and Kamal25 recruited 25 asthmatic patients and 
20 healthy controls (with differences in the mean ages 
of the groups: asthmatic=45 years and the controls=34 
years). Mean BMI did not differ between groups. The 
severity of the asthmatic group was not reported. IOS was 
used to assess asthma, with X5 and R5 being reported. 
R5 was reported in % predicted, but the X5 was reported 
in absolute values, but did not indicate the unit used. X5 
and R5 were different between the two groups (asthma: 
mean X5 −2.87±1.84 and R5% 245.24±109.18. Healthy 
controls mean X5 −0.28±0.10 and R5% 109.25±19.40). 
FEV1 was lower in the asthmatic group with a mean of 
59.68%±23.73 predicted compared with the healthy 
controls mean of 89.75%±8.70 predicted.
Koruga et al22 included 31 male military recruits in 
Serbia with a previous diagnosis of asthma. Histamine 
was used to assess bronchial hyperreactivity, recording 
the dose that decreased FEV1 by 20% predicted value 
(PD20). X5, R5 and Ax was reported at baseline and after 
PD20. They found that the overall change in FEV1 after 
PD20 was 25.66%, while the R5 and X5 had a change of 
66.64±62.91 and 132.18±148.13, respectively. No controls 
were included in the study.
Similar to Koruga et al22 and Mousa and Kamal,25 Nair 
et al26 used a Masterscreen- IOS device, but reported X5 
and R5 as % predicted values. Nair et al included 82 
patients with previous diagnosis of asthma and 61 healthy 
subjects. The asthma group was older (mean age 49 years 
vs mean age 28 years in the control group). Weight was 
not reported in either group. Nineteen per cent of the 
asthma patients were current or previous smokers, but 
the controls were all never smokers. All inhaled drugs 
such as short acting beta- agonists and long acting beta- 
agonists were withheld before reversibility testing except 
inhaled corticosteroids. Asthma severity and comorbidi-
ties were not reported. Airways reversibility was assessed 
using 400 μg of salbutamol via a metered dose inhaler and 
spacer and reported a mean change of 6.34% of FEV1 in 
the asthma group and 2.25% in the healthy controls. The 
mean percentage of change after administering salbu-
tamol was −33.78±4.43 and −72.93±88.73 in R5 and X5, 
respectively in the asthma group. In the control group, 
the mean change was −14.91±2.48 in R5 and 40.09±65.64 
in X5.
Maximal mid-expiratory flow
Guldent Pasaoglu et al30 recruited 433 asthmatic patients 
(mean age 37 years) and 152 patients with COPD (mean 
age 54 years), aiming to assess differences in clinical and 
spirometric features of asthma and COPD. 29% of the 
asthma group and 64% of the COPD group were current 
smokers. Reversibility was assessed in both groups using 
200 μg of salbutamol and defined by an increase of more 
than 12% and 200 mL of the FEV1 value. 62.1% of the 
asthma group met criteria for reversibility compared with 
39.5% in the COPD group. MMEF was the only param-
eter that was below the normal range in non- smoking 
asthmatic patients with normal auscultation, suggesting 
that MMEF was a physiological marker of asthma in 
Figure 2 (A) Graph of Agency for Healthcare Research and Quality tool for quality/risk of bias of cross- sectional studies. (B) 
Graph of Quality Assessment of Diagnostic Accuracy Studies 2 tool for diagnostic test accuracy studies.
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non- smoking asymptomatic patients. Although bron-
chodilator responses were measured, these were not 
reported.
Son et al31 conducted a retrospective study of 125 
patients with a clinical suspicion of asthma who had 
undergone an MCT. Patients were stratified into three 
groups based on their FEV1 and MMEF response to MCT. 
The positive response to MCT was considered if there was 
a decline of 20% in FEV1 and for MMEF, as well. Group 
1 included patients with negative MCT tests for both 
parameters. Group 2 included patients with a negative 
FEV1 and a positive MMEF. Group 3 included patients 
with positive test to both parameters. The mean ages of 
the included subjects were 45 years in group 1, 39 years 
in group 2 and 43 years in group 3. Eight subjects had a 
previous diagnosis of asthma, three in group 1 and five 
in group 3. Allergic rhinitis was reported in 34 subjects, 
16 of them were positive to MCT in both spirometric 
indices, therefore included in group 3. Mean baseline 
MMEF in groups 1 and 2 was 97.67%±3.48 predicted 
and 95.08%±5.74 predicted, respectively. In group 3, 
mean MMEF was 70.16%±4.64 predicted. The authors 
suggested that MMEF may be a more sensitive marker 




Li et al27 and Nikkhah et al28 assessed the DTA of IOS 
for asthma. The majority of participants in Nikkhah et al 
study were women, while Li et al27 had a majority of male 
participants. Neither study reported participants’ weight 
or BMI. Nikkhah et al cut- offs were not pre- specified, but 
were proposed after plotting an ROC curve. Li et al did 
not report a cut- off value. They both studied resistance at 
5 Hz, but reactance was studied at different frequencies 
with Li et al at 35 Hz and Nikkhah et al at 5 Hz. The sensi-
tivity of R5 was reported as 72% by Li et al and 69% by 
Nikkhah et al while specificity reported by Li et al at 61% 
and Nikkhah et al at 86%. Reactance had lower sensitivity 
in both studies. Both studies did not report the asthma 
severity of the participants or clinical comorbidities and 
Li et al did not report the FEV1 results, although they 
performed bronchodilator response tests on all partici-
pants. Figure 3A shows the pooled data of R5 of the two 
studies.
Maximal mid-expiratory flow
There was only one DTA study which used MMEF in 
asthma compared with controls (Yartsev).29 The asthma 
group was older than the control group. Both the asthma 
and control groups had a majority of female partici-
pants. Asthma severity and comorbidities of participants 
were not reported. The author stratified asthma patients 
into three groups based on the baseline FEV1. Group 1 
included participants with FEV1 of >80% predicted value, 
group 2 with FEV1 60%–80% predicted and group 3 
with FEV1 25%–60% predicted. In MMEF tests, the cut- 
off used was 90% predicted in group 1, 70% predicted 
in group 2 and 50% predicted in group 3. The DTA of 
MMEF in group 1 was a sensitivity of 66% and specificity 
of 91%. Identical results were found in groups 2 and 3 
with a sensitivity of 99% and specificity of 100%. The 
accuracy of MMEF was assessed on all groups with a cut- 
off value of 70% showed a sensitivity of 88% and speci-
ficity 97%. Using FEV1, cut- off was set at 120% predicted 
in group 1, 90% predicted in group 2, 70% predicted in 
group 3. The DTA of FEV1 in group 1 was a sensitivity of 
77% and specificity of 65%. In groups 2 and 3, identical 
sensitivity of 100% and specificity of 100% was reported. 
All groups were assessed for accuracy using FEV1, with a 
70% predicted cut- off, showing a sensitivity of 92% and 
specificity of 88%. DTA data were pooled into the forest 
plot shown in figure 3B.
Synthesis of results
Small airways function in asthma were found to be 
different when compared with healthy controls. The 
% predicted MMEF value appeared consistently lower 
than the % predicted FEV1, as shown in figure 4. In 
oscillometry, R5 was also found to be consistently higher 
in asthmatic when compared with healthy controls as 
shown in figure 5. These results highlight the presence 
of small airways limitation in asthmatic patients with 
Figure 3 (A) Diagnostic test accuracy (DTA) forest plot of R5. (B) DTA forest plot of maximal mid- expiratory flow. FN, false 
negative; FP, false positive; TN, true negative; TP, true positive.
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heterogeneous characteristics including age, ethnicity 
and weight.
Risk of bias across studies
There were some concerns of bias in regard to reporting 
outcomes. Kamal and Mousa25 reported R5 as the % 
predicted value while X5 was reported without a unit of 
measurement. Iartsev29 did not report how the cut- offs 
were determined or how subjects were recruited.
DISCUSSION
To the authors’ knowledge, this is the first systematic 
review to assess the use of physiological tests of small 
airways function in the diagnosis of asthma. Previous 
work has suggested that SAD is associated with asthma 
and that the prevalence of SAD increases with the severity 
of asthma.32 33 This review suggests that most published 
studies of small airways function tests in asthma are heter-
ogeneous, of varying methodological quality and have 
primarily identified SAD rather than using measures of 
small airways to diagnose asthma. No studies reported 
the severity of asthma in the participants and participants 
groups were often poorly matched or characterised in 
terms of other comorbidities and weight.
This review focuses on MMEF and oscillometry and 
does not explore all potential measures to assess small 
airways function. MMEF and oscillometry were chosen 
as these represented the most commonly cited small 
airways measures. The clinical utility of oscillometry 
techniques has been described in asthma and other lung 
conditions such as interstitial lung diseases and COPD.19 
Oscillometry has been suggested as a useful tool in diag-
nosing asthma in children.34 However, there remains a 
lack of universal reference ranges, especially in adults. 
Height23 and sex35 appear to alter values. Oostveen et al35 
Figure 4 Comparison of % predicted of MMEF to FEV1 in asthmatic patients. FEV1, forced expiratory volume in 1 s; MMEF, 
maximal mid- expiratory flow.
Figure 5 Comparison of R5 between asthmatic patients to healthy controls.
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conducted a multicentre study on healthy subjects in an 
effort to produce reference ranges for oscillometry in 
adults, but only one ethnicity was studied. Another study 
was also conducted in Japan to establish reference ranges 
for Japanese adults.36 Understanding and interpreting 
oscillometry remains challenging. In this review, it was 
unclear if oscillometry studies provided the most robust 
measure of small airways function. The R5–R20 (often 
referred to as resistance of the small airways) was only 
reported by Mori et al.24 Airways reversibility, a hallmark 
of asthma, was only assessed using oscillometry by Nair et 
al26 and, here, the mean percentage change in the FEV1 
in the asthma group was 6.34%, which is less than the 
standard reversibility change of 12%.
The MMEF is an effort- dependent test and guide-
lines for reproducibility of the manoeuvre is based 
on FVC and FEV1.
37 In all the included articles that 
studies MMEF, the % predicted of MMEF was found to 
be lower in asthmatic groups compared with control 
groups. Moreover, the % predicted value of MMEF 
was lower than the % predicted FEV1 in the asthmatic 
group, suggesting that small airways limitation might be 
an early marker of airways obstruction. The potential 
utility of MMEF in early disease was described in one 
study of patients with alpha-1 antitrypsin deficiency, 
where an MMEF less than 80% predicted, with a normal 
FEV1/FVC ratio, was associated with increased respira-
tory symptoms and a faster decline in FEV1 compared 
with those with an MMEF of 80% or greater and normal 
spirometry, suggesting a role for MMEF in early disease 
monitoring.38
There are significant limitations to the evidence base 
described in this review including study heterogeneity, 
poor patient characterisation and differences in reported 
values. Not all tests of small airways function have been 
assessed in asthma (eg, MBW). There are no universally 
accepted predicted values for oscillometry, especially in 
adults, making the interpretation of the results more diffi-
cult. Oscillation techniques produce many parameters in 
both inspiratory and expiratory phases and the differ-
ences in reported values limits comparisons between 
studies. MMEF was not corrected for FVC in any study, 
and this is a limitation as MMEF is a timed/flow measure-
ment and FVC exhalation curve changes may affect the 
results.39 Nevertheless, most studies provide at least some 
signal of SAD in asthma suggesting these indices could 
be helpful in diagnosing and monitoring asthma. To 
take this field forward, further research is needed. This 
should include standardising the assessment of small 
airways tests (although different tests may have greater 
or lesser utility in different diseases) and forming normal 
reference ranges to aid interpretation. Studies in asthma 
need to predefine how asthma was diagnosed, and report 
clearly which small airways tests have been measured, by 
what device, what units are reported and what would be 
considered an abnormal result or clinically meaningful 
change in a specified value.
CONCLUSION
Physiological tests of small airways function are feasible 
in diagnosing asthma and have been shown to be altered 
in asthma when compared with healthy adults. However, 
a lack of robust reference ranges and the heterogeneity 
of approach complicate their use.
Further studies are needed to assess small airways func-
tion in asthma, especially in early disease. Larger studies 
are needed to assess the impact of demographic char-
acteristics and comorbidities such as obesity or allergic 
rhinitis. This systematic review of current literature 
suggests these tests may have promise as part of the future 
diagnostic criteria of asthma, but more work is needed 
before they can be embedded into clinical care.
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